Publications

484 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease

The National Health Care Institute has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is ...

Report | 19-03-2020
Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps

The National Health Care Institute has assessed whether hydroquinine (Inhibin®) should be included in the medication ...

Report | 04-03-2020
Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations

The National Health Care Institute has completed its assessment whether voretigene neparvovec (Luxturna®) for the treatment of ...

Report | 17-02-2020
Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors

The National Health Care Institute has completed its assessment whether emicizumab (Hemlibra®) for the prophylactic treatment of ...

Report | 17-02-2020
GVS assessment of Bevespi® aerosphere for the treatment of COPD

The National Health Care Institute has completed its assessment whether Bevespi® aerosphere for the treatment of COPD, can be ...

Report | 27-01-2020
GVS assessment of racecadotril (Hidrasec®) for the treatment of acute diarrhoea in infants (over 3 months of age) and children

The National Health Care Institute has completed its assessment whether racecadotril (Hidrasec®) is interchangeable with another ...

Report | 17-12-2019
GVS assessment of a 4 component meningococcal B vaccine (Bexsero®)

The National Health Care Institute has completed its assessment whether the product 4 component meningococcal B vaccine (4CMenB) ...

Report | 16-12-2019
GVS assessment of hydrocortisone (Alkindi®) for the treatment of adrenal insufficiency

The National Health Care Institute has completed its assessment whether hydrocortisone (Alkindi®) can be included in the ...

Report | 10-12-2019
Metreleptin (Myalepta®) for treatment of lipodystrophy

Zorginstituut Nederland has completed its assessment whether metreleptin (Myalepta®) for treatment of lipodystrophy can be ...

Report | 21-10-2019
GVS assessment of extension of further conditions for GLP-1ra

The minister for Medical Care asked Zorginstituut Nederland to extend the further conditions for the glucagon-like peptide 1 ...

Report | 26-09-2019

Publications

484 publications

Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease

Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps

Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations

Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors

GVS assessment of Bevespi® aerosphere for the treatment of COPD

GVS assessment of racecadotril (Hidrasec®) for the treatment of acute diarrhoea in infants (over 3 months of age) and children

GVS assessment of a 4 component meningococcal B vaccine (Bexsero®)

GVS assessment of hydrocortisone (Alkindi®) for the treatment of adrenal insufficiency

Metreleptin (Myalepta®) for treatment of lipodystrophy

GVS assessment of extension of further conditions for GLP-1ra

Go to